Issue 3, 2016

eCF309: a potent, selective and cell-permeable mTOR inhibitor


Kinase inhibitors capable of blocking the phosphorylation of protein substrates with high selectivity are essential to probe and elucidate the etiological role of such molecules and their signalling pathways. By addressing these biochemical questions in disease relevant cell-based and in vivo models, strong pharmacological evidence can be generated towards validating or disproving a target hypothesis. Pharmacological studies can also provide fundamental information to identify appropriate biomarkers and rational drug combination strategies and thereby facilitate clinical translation. However, due to the high number of kinases encoded by the human genome (>500) and their highly conserved catalytic domains, the development of such an elite class of inhibitors—a.k.a. high-quality chemical probes—represents a major challenge. Through a ligand-based inhibitor design, focused library synthesis and phenotypic screening to prioritize compounds with potent cell activity, we recently identified a cell cycle inhibitor with micromolar potency that inhibits mTOR kinase activity. Following a rapid lead optimization campaign, we report the development of eCF309, an mTOR inhibitor displaying low nanomolar potency both in vitro and in cells and an excellent selectivity profile (S-score (35%) = 0.01 at 10 μM).

Graphical abstract: eCF309: a potent, selective and cell-permeable mTOR inhibitor

Associated articles

Supplementary files

Article information

Article type
Research Article
26 Oct 2015
10 Dec 2015
First published
22 Dec 2015
This article is Open Access
Creative Commons BY license

Med. Chem. Commun., 2016,7, 471-477

eCF309: a potent, selective and cell-permeable mTOR inhibitor

C. Fraser, N. O. Carragher and A. Unciti-Broceta, Med. Chem. Commun., 2016, 7, 471 DOI: 10.1039/C5MD00493D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.